Genenta Science SpA ADR (GNTA) - Total Assets
Based on the latest financial reports, Genenta Science SpA ADR (GNTA) holds total assets worth $31.89 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Genenta Science SpA ADR - Total Assets Trend (2019–2025)
This chart illustrates how Genenta Science SpA ADR's total assets have evolved over time, based on quarterly financial data. Also see GNTA stock market capitalisation for the company's overall valuation and market capitalisation.
Genenta Science SpA ADR - Asset Composition Analysis
Current Asset Composition (December 2025)
Genenta Science SpA ADR's total assets of $31.89 Million consist of 94.0% current assets and 6.0% non-current assets. Review Genenta Science SpA ADR total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 17.3% |
| Accounts Receivable | $1.29 Million | 4.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Genenta Science SpA ADR's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Genenta Science SpA ADR stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genenta Science SpA ADR's current assets represent 94.0% of total assets in 2025, a decrease from 96.5% in 2019.
- Cash Position: Cash and equivalents constituted 17.3% of total assets in 2025, down from 94.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 4.0% of total assets.
Genenta Science SpA ADR Competitors by Total Assets
Key competitors of Genenta Science SpA ADR based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Genenta Science SpA ADR - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.16 | 9.30 | 7.26 |
| Quick Ratio | 14.16 | 9.30 | 7.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $27.86 Million | $16.57 Million | $10.44 Million |
Genenta Science SpA ADR - Advanced Valuation Insights
This section examines the relationship between Genenta Science SpA ADR's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.88 |
| Latest Market Cap to Assets Ratio | 0.52 |
| Asset Growth Rate (YoY) | 115.1% |
| Total Assets | $31.89 Million |
| Market Capitalization | $16.45 Million USD |
Valuation Analysis
Below Book Valuation: The market values Genenta Science SpA ADR's assets below their book value (0.52x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Genenta Science SpA ADR's assets grew by 115.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Genenta Science SpA ADR (2019–2025)
The table below shows the annual total assets of Genenta Science SpA ADR from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $31.89 Million | +115.12% |
| 2024-12-31 | $14.82 Million | -33.66% |
| 2023-12-31 | $22.35 Million | -33.17% |
| 2022-12-31 | $33.44 Million | -16.46% |
| 2021-12-31 | $40.03 Million | +128.70% |
| 2020-12-31 | $17.50 Million | -18.02% |
| 2019-12-31 | $21.35 Million | -- |
About Genenta Science SpA ADR
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for us… Read more